National Health Insurance Service Ilsan Hospital Researcher Provides New Insights into Heart Attack (Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction): Heart Disorders and Diseases – Heart Attack

2023 SEP 13 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Cardiovascular Daily -- Data detailed on heart attack have been presented. According to news originating from Goyang, South Korea, by NewsRx correspondents, research stated, “Conflicting results have been reported regarding the interaction between proton pump inhibitors (PPIs) and clopidogrel. We investigated whether concomitant PPI use influenced the risk of recurrence in patients with stroke and myocardial infarction (MI).”

Funders for this research include National Health Insurance Service Ilsan Hospital Grant; Korean College of Helicobacter And Upper Gastrointestinal Research Foundation Grant.

Our news journalists obtained a quote from the research from National Health Insurance Service Ilsan Hospital: “This study used two databases for two different designs, the Korean National Health Insurance Service (NHIS) database for a self-controlled case series design, and the national sample cohort of the NHIS data base converted to the Observational Medical Partnership-Common Data Model version for a cohort study based on large-scale propensity score matching. In the PPI co-prescription group, recurrent hospitalization with stroke occurred in 17.6% of the 8201 patients with history of stroke, and recurrent MI occurred in 17.1% of the 1216 patients with history of MI within1 year. According to the self-controlled case series, the overall relative risk (RR) of recurrent stroke was 2.09 (95% confidence interval (CI); 1.83-2.38); the RR showed an increasing trend parallel to the time from the beginning of PPI co-prescription. In the cohort study, there was a higher incidence of recurrent stroke in the PPI co-prescription group (Hazard ratio (HR): 1.34, 95% CI: 1.01-1.76, p = 0.04). The overall RR of recurrent MI was 1.47 (95% CI; 1.02-2.11) in the self-controlled case series; however, there was no statistically significant difference in recurrent MI in the cohort study (HR:1.42, 95% CI:0.79-2.49, p = 0.23). The impact of individual PPIs on stroke and MI showed different patterns.”

According to the news reporters, the research concluded: “A PPI co-prescription >4 weeks with clopidogrel was associated with hospitalization of recurrent stroke within 1 year of initial diagnosis; however, its association with recurrent MI remains inconclusive. The influence of individual PPIs should be clarified in the future.”

For more information on this research see: Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction. Pharmaceuticals, 2023,16(9). (Pharmaceuticals - http://www.mdpi.com/journal/pharmaceuticals/). The publisher for Pharmaceuticals is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/ph16091213.

Our news editors report that additional information may be obtained by contacting Yong Kang Lee, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, South Korea. Additional authors for this research include Hyun Sun Lim, Youn I Choi, Eun Ju Choe, Seonji Kim, Seng Chan You, Kyung Joo Lee, Yerim Kim, Da Hee Park, Woon Geon Shin, Seung In Seo.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the authors of this research: Eun Ju Choe (http://orcid.org/0000-0002-0012-472X), Seonji Kim (http://orcid.org/0000-0002-4993-7537), Woon Geon Shin (http://orcid.org/0000-0002-9851-5576), Seung In Seo (http://orcid.org/0000-0003-4417-0135).

(Our reports deliver fact-based news of research and discoveries from around the world.)